<?xml version="1.0"?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text xml:lang="en">
			<front>Medicinal Chemistry Research (2018) 27:2051-2061 <lb/>https://doi.org/10.1007/s00044-018-2213-x <lb/>MEDICINAL <lb/>CHEMISTRY <lb/>RESEARCH <lb/>REVIEW ARTICLE <lb/>Novel triazoles of 3-acetylbetulin and betulone as anticancer agents <lb/>Ewa Bębenek 1 • Monika Kadela-Tomanek 1 • Elwira Chrobak 1 • Małgorzata Latocha 2 • Stanisław Boryczka 1 <lb/>Received: 13 April 2018 / Accepted: 27 June 2018 / Published online: 17 July 2018 <lb/>© The Author(s) 2018 <lb/>Abstract <lb/>The CuAAC reaction of azides and acetylenic triterpenes was used for synthesis of new triazoles of 3-acetylbetulin and <lb/>betulone. The triazole derivatives were evaluated for their anticancer activity in vitro against amelanotic melanoma C-32, <lb/>ductal carcinoma T47D and glioblastoma SNB-19 cell lines. 28-[1-(3&apos;-Deoxythymidine-5&apos;-yl)-1H-1,2,3-triazol-4-yl] <lb/>carbonylbetulone 6e exhibited a significant IC 50 value (0.17 µM) against the human glioblastoma SNB-19 cell line, an <lb/>almost 5-fold higher potency while compared with reference cisplatin. <lb/>Keywords Betulin • 1,2,3-Triazole • CuAAC • Anticancer activity • Lipophilicity <lb/></front>

			<body>Introduction <lb/>The cycloaddition reaction plays an important role in the <lb/>synthesis of five-membered heterocyclic structures such as <lb/>1,2,3-triazoles. Molecules containing a 1,4-disubstituted <lb/>1,2,3-triazole ring are prepared regioselectively from azides <lb/>and terminal alkynes in the copper-(I)-catalyzed azide-<lb/>alkyne cycloaddition reaction CuAAC (Wei et al. 2012; <lb/>Marciniec et al. 2017). CuAAC reactions, described by <lb/>Sharpless and Meldal groups, give high yields under mild <lb/>conditions and have been used to obtain drugs, photo sta-<lb/>bilizers and dyes. Additionally, this reaction occurs in <lb/>various organic solvents and in aqueous media, in a wide <lb/>pH area. In contrast to the CuACC reaction, the ruthenium <lb/>catalyst azide-alkyne cycloaddition is used in the synthesis <lb/>of the 1,5-disubstituted triazoles (Rostovtsev et al. 2002; <lb/>Torne et al. 2002; Bonacorso et al. 2013; Bräse et al. 2008; <lb/>Totobenazara et al. 2015). <lb/>Compounds containing 1,2,3-triazole units exhibit <lb/>interesting biological activities (antimicrobial, anti-inflam-<lb/>matory, anti-tubercular, and antiviral), which has found <lb/>numerous applications in bioconjugate chemistry and <lb/>material science. Additionally, 1,4-disubstitued 1,2,3-tria-<lb/>zoles show a significant anticancer activity against human <lb/>cancer cell lines, which are multidrug-resistant (Wang et al. <lb/>2010; Dheer et al. 2017; He et al. 2014). <lb/>In the last decades, application of 1,3-dipolar cycload-<lb/>diction of naturally occurring triterpenes acquired meaning. <lb/>Conjugation on azides with various alkyne derivatives of <lb/>pentacyclic triterpenes is designed for the purposes of <lb/>introduction of the physiologically stable 1,2,3-triazole <lb/>group (Spivak et al. 2016; Suman et al. 2016; Yu et al. <lb/>2013). Most of the triazole analogs of natural compounds <lb/>have been investigated for their anticancer activity. Majeed <lb/>et al. synthesized and tested a series of C-3 aryl-substituted <lb/>1,2,3-triazoles of betulinic acid for their cytotoxic activity <lb/>against various human cancer lines like leukemia (HL-60, <lb/>THP-1), prostate (DU-145, PC-3), lung (A-549), breast <lb/>(MCF-7), liver (HEP-2), colon (HCT-15), and neuro-<lb/>blastoma (SF-295). The compounds bearing 2-cyanophenyl <lb/>and 5-hydroxy-1-naphthyl substituted triazole ring exhib-<lb/>ited promising IC 50 values against HL-60 cell line of 2.5 <lb/>and 3.5 µM, respectively, in comparison to betulinic acid <lb/>(IC 50 = 17 µM) (Majeed et al. 2013). In the case of C-28 <lb/>aryl-substituted 1,2,3-triazoles of betulinic acid, it was <lb/>observed that compounds containing a 4-fluorophenyl <lb/>substituted triazole ring had the cytotoxic profile similar <lb/>to that of betulinic acid. This novel triazole hybrid showed a <lb/>significant antiproliferative activity in HL-60 (leukemia), <lb/></body>

			<front>* Ewa Bębenek <lb/>ebebenek@sum.edu.pl <lb/>1 <lb/>Department of Organic Chemistry, School of Pharmacy with the <lb/>Division of Laboratory Medicine in Sosnowiec, Medical <lb/>University of Silesia in Katowice, 4 Jagiellońska Str., 41-200 <lb/>Sosnowiec, Poland <lb/>2 <lb/>Department of Cell Biology, School of Pharmacy with the <lb/>Division of Laboratory Medicine in Sosnowiec, Medical <lb/>University of Silesia in Katowice, 8 Jedności Str., 41-200 <lb/>Sosnowiec, Poland <lb/>1234567890();,: <lb/>1234567890();,: <lb/></front>

			<body>MIAPACa2 (pancreas), PC-3 (prostate), and A-549 (lung) <lb/>cell lines, with IC 50 values in the range of 5.0-7.0 µM <lb/>(Khan et al. 2016). <lb/>Previously, we described a synthetic route and evaluation <lb/>of cytotoxicity of betulin and betulone derivatives with a <lb/>propynoyl group at the C-28 position (Boryczka et al. 2013; <lb/>Bębenek et al. 2016). Expanding our interest to propynoyl-<lb/>substituted triterpenes, we converted those acetylenic deri-<lb/>vatives into the corresponding 1,2,3-triazoles. In this work, <lb/>we presented application of the CuAAC reaction in the <lb/>synthesis of new triazoles of pentacyclic triterpenes and <lb/>their anticancer activity, as well as lipophilicity properties. <lb/>Material and methods <lb/>General <lb/>All organic solvents (from Sigma-Aldrich and P.P.H. <lb/>STANLAB) were dried and used after purification. Melting <lb/>points (m.p.) were determined in open capillary tubes on an <lb/>Electrothermal IA 9300 melting point apparatus and are <lb/>uncorrected. The 1 H NMR and 13 C NMR spectra were <lb/>recorded on a Bruker Avance III 600 spectrometer in <lb/>deuterated-d 6 chloroform (CDCl 3 ) or deuterated-d 6 dimethyl <lb/>sulfoxide (DMSO) solution. The chemical shifts were <lb/>reported in ppm (δ), and coupling constant (J) values-in <lb/>hertz (Hz). The spin multiplicity was designated as the <lb/>singlet (s), doublet (d), triplet (t), quartet (q), and multiplet <lb/>(m). High-resolution mass spectra (HR-MS) were recorded <lb/>on a Bruker Impact II instrument. Infrared spectra (IR) were <lb/>recorded on a Shimadzu IRAffinity-1 FTIR spectro-<lb/>photometer (Shimadzu, Japan) using the KBr pellet method. <lb/>The progress of the reactions was monitored by thin layer <lb/>chromatography (TLC) using silica gel 60 254 F plates <lb/>(Merck, Darmstadt, Germany) and detected by spraying <lb/>with a solution of 5% sulfuric (VI) acid and heating to 120 <lb/>°C. <lb/>Purity of the obtained compounds was confirmed by <lb/>column chromatography carried out on silica gel 60, <lb/>&lt;63 μm (Merck). A mixture of CHCl 3 -EtOH (40:1, 15:1, <lb/>5:1 v/v) or CH 2 Cl 2 -EtOH (60:1, 40:1, v/v) was used as the <lb/>mobile phase. <lb/>Chemistry <lb/>Synthesis of 3-acetyl-28-propynoylbetulin 3 and 28-<lb/>propynoylbetulone 4 <lb/>3-Acetyl-28-propynoylbetulin 3 was prepared according to <lb/>the procedure described by Boryczka et al. (Boryczka et al. <lb/>2013). <lb/>To an ice-cooled (-10 °C) mixture of 3-acetylbetulin 2 <lb/>(0.48 g, 1 mmol) and propynoic acid (0.12 g, 1.10 mmol) in <lb/>dichloromethane (5 mL), a freshly prepared solution of <lb/>dicyclohexylcarbodiimide (0.23 g, 1.12 mmol) and 4-<lb/>dimethylaminopyridine (0.01 g, 0.08 mmol) in dichlor-<lb/>omethane (1 mL) was added. The mixture was allowed to <lb/>react under argon atmosphere at -10 °C for 5 h. After <lb/>warming to room temperature, the mixture was stirred <lb/>overnight. The reaction was monitored by TLC until com-<lb/>pletion. The resulting precipitate was filtered and the sol-<lb/>vent was removed under reduced pressure. The crude <lb/>product was purified by silica gel column chromatography <lb/>(CHCl 3 -EtOH 40:1, v/v). <lb/>3-Acetyl-28-propynoylbetulin <lb/>(3) Yield <lb/>79%; <lb/>mp <lb/>115-118 °C; R f 0.44 (CHCl 3 -EtOH, 40:1, v/v); IR (KBr) <lb/>ν max 3304, 2946, 2120, 1719, 1457, 1246 cm -1 ; 1 H NMR <lb/>(600 MHz, CDCl 3 ): δ 0.81 (3H, s, CH 3 ), 0.86 (3H, s, CH 3 ), <lb/>0.87 (3H, s, CH 3 ), 0.99 (3H, s, CH 3 ), 1.05 (3H, s, CH 3 ), <lb/>2.07 (3H, s, COCH 3 ), 2.45 (1H, m, H-19), 2.91 (1H, s, <lb/>C≡CH), 4.01 (1H, d, J = 10.8 Hz, H-28), 4.41 (1H, d, J = <lb/>10.8 Hz, H-28), 4.48 (1H, m, H-3), 4.62 (1H, s, H-29), 4.71 <lb/>(1H, s, H-29); 13 C NMR (150 MHz, CDCl 3 ): δ 14.7, 16.0, <lb/>16.2, 16.5, 18.2, 19.1, 20.8, 21.3, 23.7, 25.1, 27.0, 27.9, <lb/>29.5, 29.6, 34.1, 34.4, 37.1, 37.7, 37.8, 38.4, 40.9, 42.7, <lb/>46.4, 47.7, 48.8, 50.3, 55.4, 64.9, 74.6, 74.8, 80.9, 110.0, <lb/>149.9, 153.3, 171.0; HRAPCIMS m/z: 536.3878 C 35 H 52 O 4 <lb/>(calcd. 536.3865). <lb/>28-Propynoylbetulone 4 was obtained according to the <lb/>procedure described by Bębenek et al. The spectra data of <lb/>Table 1 The mobile phases used in column chromatography and <lb/>calculated values of the retention factor <lb/>Compound <lb/>Mobile phase <lb/>Ratio <lb/>Retention factor R f <lb/>5a <lb/>CH 2 Cl 2 -EtOH <lb/>60:1 <lb/>0.39 <lb/>5b <lb/>CH 2 Cl 2 -EtOH <lb/>40:1 <lb/>0.55 <lb/>5c <lb/>CH 2 Cl 2 -EtOH <lb/>60:1 <lb/>0.32 <lb/>5d <lb/>CH 2 Cl 2 -EtOH <lb/>60:1 <lb/>0.43 <lb/>5e <lb/>CHCl 3 -EtOH <lb/>5:1 <lb/>0.68 <lb/>5f <lb/>CHCl 3 -EtOH <lb/>5:1 <lb/>0.18 <lb/>5g <lb/>CH 2 Cl 2 -EtOH <lb/>40:1 <lb/>0.43 <lb/>5h <lb/>CHCl 3 -EtOH <lb/>15:1 <lb/>0.45 <lb/>5i <lb/>CHCl 3 -EtOH <lb/>5:1 <lb/>0.73 <lb/>6a <lb/>CH 2 Cl 2 -EtOH <lb/>40:1 <lb/>0.43 <lb/>6b <lb/>CH 2 Cl 2 -EtOH <lb/>40:1 <lb/>0.49 <lb/>6c <lb/>CH 2 Cl 2 -EtOH <lb/>60:1 <lb/>0.36 <lb/>6d <lb/>CH 2 Cl 2 -EtOH <lb/>60:1 <lb/>0.37 <lb/>6e <lb/>CHCl 3 -EtOH <lb/>15:1 <lb/>0.24 <lb/>6f <lb/>CHCl 3 -EtOH <lb/>5:1 <lb/>0.22 <lb/>6g <lb/>CH 2 Cl 2 -EtOH <lb/>60:1 <lb/>0.31 <lb/>6h <lb/>CHCl 3 -EtOH <lb/>15:1 <lb/>0.32 <lb/>6i <lb/>CHCl 3 -EtOH <lb/>5:1 <lb/>0.74 <lb/>6j <lb/>CHCl 3 -EtOH <lb/>5:1 <lb/>0.20 <lb/></body>

			<page>2052 <lb/></page>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<body>acetylenic ester 4 were consistent with those published in <lb/>the literature (Bębenek et al. 2016). <lb/>General procedure for the synthesis of triazoles 5a-i and <lb/>6a-j <lb/>Based on the previously reported method, the acetylenic <lb/>esters 3-4 were converted into triazoles 5a-i and 6a-j by <lb/>reactions with organic azides in toluene in the presence of <lb/>copper(I) iodide (Bębenek et al. 2017). The copper(I) iodide <lb/>(0.1 eqv, 0.004 g, 0.02 mmol) and the organic azide (1.05 <lb/>eqv, 0.21 mmol) were added to a solution of propynoylated <lb/>derivatives 3 or 4 (0.20 mmol) in toluene (4 mL). Next, the <lb/>reaction mixture was stirred for another 72 h under reflux. <lb/>The solvent was evaporated. The crude residue was purified <lb/>by silica gel column chromatography using various mix-<lb/>tures of organic solvents. The same mobile phases were <lb/>applied for TLC and in column chromatography (Table 1). <lb/>3-Acetyl-28-(1-benzyl-1H-1,2,3-triazol-4-yl)carbonylbetulin <lb/>(5a) Yield 73%; m.p. 109-111 °C; IR (KBr) ν max 3134, <lb/>2947, 1732, 1527, 1456, 1246-1193 cm -1 ; 1 H NMR <lb/>(600 MHz, CDCl 3 ): δ 0.85 (3H, s, CH 3 ), 0.86 (3H, s, CH 3 ), <lb/>0.87 (3H, s, CH 3 ), 0.99 (3H, s, CH 3 ), 1.06 (3H, s, CH 3 ), <lb/>1.71 (3H, s, CH 3 ), 2.06 (3H, s, COCH 3 ), 2.51 (1H, m, H-<lb/>19), 4.13 (1H, d, J = 10.8 Hz, H-28), 4.49 (1H, m, H-3), <lb/>4.55 (1H, d, J = 10.8 Hz, H-28), 4.62 (1H, s, H-29), 4.72 <lb/>(1H, s, H-29), 5.60 (2H, s, CH 2 ), 7.31-7.33 (2H, m, H Ar ), <lb/>7.41-7.44 (3H, m, H Ar ), 7.97 (1H, s, CH-triazole); 13 C <lb/>NMR (150 MHz, CDCl 3 ): δ 14.2, 14.7, 16.0, 16.2, 16.5, <lb/>18.2, 19.1, 20.8, 21.1, 21.3, 23.7, 25.2, 27.1, 27.9, 29.6, <lb/>29.8, 34.1, 34.7, 37.1, 37.7, 38.4, 40.9, 42.7, 46.7, 47.7, <lb/>48.9, 50.3, 54.5, 55.4, 60.4, 63.6, 80.9, 109.9, 127.1, 128.2, <lb/>129.2, 129.3, 133.8, 140.6, 150.1, 161.2, 171.1; HRAP-<lb/>CIMS m/z (neg): 668.4474 C 42 H 58 N 3 O 4 (calcd. 668.4427). <lb/>3-Acetyl-28-[1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl]carbo-<lb/>nylbetulin (5b) Yield 63%; m.p. 113-116 °C; IR (KBr) <lb/>ν max 3138, 2963, 1734, 1539, 1457, 1226-1193, 802 cm -1 ; <lb/>1 H NMR (600 MHz, CDCl 3 ): δ 0.85 (3H, s, CH 3 ), 0.86 (3H, <lb/>s, CH 3 ), 0.87 (3H, s, CH 3 ), 1.00 (3H, s, CH 3 ), 1.06 (3H, s, <lb/>CH 3 ), 1.69 (3H, s, CH 3 ), 2.07 (3H, s, COCH 3 ), 2.52 (1H, m, <lb/>H-19), 4.14 (1H, d, J = 10.8 Hz, H-28), 4.49 (1H, m, H-3), <lb/>4.57 (1H, d, J = 10.8 Hz, H-28), 4.62 (1H, s, H-29), 4.72 <lb/>(1H, s, H-29), 5.57 (2H, s, CH 2 ), 7.10-7.13 (2H, m, H Ar ), <lb/>7.31-7.33 (2H, m, H Ar ), 7.97 (1H, s, CH-triazole); 13 C <lb/>NMR (150 MHz, CDCl 3 ): δ 13.7, 15.1, 15.2, 15.5, 17.1, <lb/>18.1, 19.8, 20.3, 22.7, 24.1, 26.1, 26.9, 28.6, 28.8, 33.1, <lb/>33.7, 36.0, 36.6, 36.8, 37.4, 39.9, 41.7, 45.6, 46.7, 47.8, <lb/>49.3, 52.7, 54.4, 62.6, 79.9, 108.9, 115.3, 115.4, 125.9, <lb/>129.1, 129.2, 139.7, 149.0, 160.0, 161.2, 170.0; HRAP-<lb/>CIMS m/z (neg): 686.4357 C 42 H 57 FN 3 O 4 (calcd. 686.4333). <lb/>3-Acetyl-28-[1-(4-cyanobenzyl)-1H-1,2,3-triazol-4-yl]carbo-<lb/>nylbetulin (5c) Yield 56%; m.p. 137-140 °C; IR (KBr) <lb/>ν max 3144, 2949, 2231, 1734, 1540, 1457, 1248-1192 cm <lb/>-1 ; 1 H NMR (600 MHz, CDCl 3 ): δ 0.83 (3H, s, CH 3 ), 0.86 <lb/>(3H, s, CH 3 ), 0.87 (3H, s, CH 3 ), 1.00 (3H, s, CH 3 ), 1.07 <lb/>(3H, s, CH 3 ), 1.70 (3H, s, CH 3 ), 2.07 (3H, s, COCH 3 ), 2.52 <lb/>(1H, m, H-19), 4.16 (1H, d, J = 10.8 Hz, H-28), 4.49 (1H, <lb/>m, H-3), 4.58 (1H, d, J = 10.8 Hz, H-28), 4.63 (1H, s, H-<lb/>29), 4.72 (1H, s, H-29), 5.68 (2H, s, CH 2 ), 7.40 (2H, d, J = <lb/>8.4 Hz, H Ar ), 7.72 (2H, d, J = 8.4 Hz, H Ar ), 8.04 (1H, s, <lb/>CH-triazole); 13 C NMR (150 MHz, CDCl 3 ): δ 14.8, 16.0, <lb/>16.2, 16.5, 18.2, 19.1, 19.3, 20.8, 21.3, 23.7, 25.2, 27.1, <lb/>27.9, 29.6, 29.8, 34.1, 34.7, 37.1, 37.7, 37.8, 38.4, 40.9, <lb/>42.7, 46.7, 47.7, 48.9, 50.3, 53.7, 55.4, 63.8, 80.9, 110.3, <lb/>113.3, 117.9, 124.4, 127.3, 128.5, 133.1, 138.9, 141.0, <lb/>150.0, 160.9, 171.0; HRAPCIMS m/z (neg): 693.4352 <lb/>C 43 H 57 N 4 O 4 (calcd. 693.4380). <lb/>3-Acetyl-28-(1-phenylthiomethyl-1H-1,2,3-triazol-4-yl)car-<lb/>bonylbetulin (5d) Yield 60%; m.p. 105-107 °C; IR (KBr) <lb/>ν max 2945, 1734, 1539,1456, 1247-1194 cm -1 ; 1 H NMR <lb/>(600 MHz, CDCl 3 ): δ 0.86 (3H, s, CH 3 ), 0.87 (3H, s, CH 3 ), <lb/>0.88 (3H, s, CH 3 ), 1.01 (3H, s, CH 3 ), 1.09 (3H, s, CH 3 ), <lb/>1.71 (3H, s, CH 3 ), 2.07 (3H, s, COCH 3 ), 2.51 (1H, m, H-<lb/>19), 4.14 (1H, d, J = 10.8 Hz, H-28), 4.49 (1H, m, H-3), <lb/>4.55 (1H, d, J = 10.8 Hz, H-28), 4.63 (1H, s, H-29), 4.73 <lb/>(1H, s, H-29), 5.68 (2H, s, CH 2 ), 7.35-7.36 (5H, m, H Ar ), <lb/>8.04 (1H, s, CH-triazole); 13 C NMR (150 MHz, CDCl 3 ): δ <lb/>14.8, 16.1, 16.2, 16.5, 18.2, 19.1, 20.8, 21.3, 23.7, 25.2, <lb/>25.6, 27.1, 27.9, 29.6, 29.8, 34.1, 34.7, 37.1, 37.7, 37.8, <lb/>38.4, 40.9, 42.7, 46.7, 47.8, 48.9, 50.3, 54.3, 55.4, 63.6, <lb/>68.0, 80.9, 110.0, 126.8, 129.1, 129.7, 131.3, 132.4, 140.6, <lb/>150.0, 160.9, 171.0; HRAPCIMS m/z (neg): 700.4141 <lb/>C 42 H 58 N 3 O 4 S (calcd. 700.4148). <lb/>3-Acetyl-28-[1-(3&apos;-deoxythymidine-5&apos;-yl)-1H-1,2,3-triazol-4-<lb/>yl]carbonylbetulin (5e) Yield 65%; m.p. 204-207 °C; IR <lb/>(KBr) ν max 3446, 3068, 2945, 1730, 1541, 1456, <lb/>1246-1192 cm -1 ; 1 H NMR (600 MHz, DMSO-d 6 ): δ 0.81 <lb/>(3H, s, CH 3 ), 0.83 (3H, s, CH 3 ), 0.98 (3H, s, CH 3 ), 1.02 <lb/>(3H, s, CH 3 ), 1.18 (3H, s, CH 3 ), 1.67 (3H, s, CH 3 ), 1.78 <lb/>(3H, s, CH 3 -AZT), 2.03 (3H, s, COCH 3 ), 2.55 (1H, m, <lb/>AZT), 2.67 (1H, m, H-19), 3.65-3.70 (2H, m, AZT), 4.03 <lb/>(1H, d, J = 10.8 Hz, H-28), 4.27 (1H, t, J = 4.8 Hz, AZT), <lb/>4.38 (1H, m, H-3), 4.55 (1H, d, J = 10.8 Hz, H-28), 4.59 <lb/>(1H, s, H-29), 4.73 (1H, s, H-29), 5.28 (1H, t, J = 4.8 Hz, <lb/>AZT), 5.46 (1H, m, AZT), 6.44 (1H, t, J = 6.6 Hz, AZT), <lb/>7.82 (1H, s, AZT), 8.32 (1H, s, CH-triazole), 9.01 (1H, s, <lb/>NH-AZT); 13 C NMR (150 MHz, DMSO-d 6 ): δ 12.7, 14.9, <lb/>15.9, 16.1, 16.3, 16.9, 18.2, 19.3, 20.8, 21.5, 23.8, 25.3, <lb/>27.1, 28.1, 29.4, 29.7, 34.0, 34.6, 37.1, 37.6, 37.7, 37.8, <lb/>38.2, 42.8, 46.8, 47.5, 48.7, 49.9, 55.0, 55.6, 60.2, 61.1, <lb/>62.7, 79.6, 80.4, 84.6, 110.1, 110.5, 129.3, 136.7, 139.3, <lb/></body>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<page>2053 <lb/></page>

			<body>150.9, 160.9, 164.2; 170.6; HRAPCIMS m/z (neg): <lb/>802.4768 C 45 H 64 N 5 O 8 (calcd. 802.4755). <lb/>3-Acetyl-28-[1-(1-deoxy-β-D-glucopyranosyl)-1H-1,2,3-tria-<lb/>zol-4-yl]carbonylbetulin (5f) Yield 82%; m.p. 210-212 °C; <lb/>IR (KBr) ν max 3419, 2943, 1732, 1543, 1456, <lb/>1246-1191 cm -1 ; 1 H NMR (600 MHz, DMSO-d 6 ): δ 0.80 <lb/>(3H, s, CH 3 ), 0.81 (3H, s, CH 3 ), 0.83 (3H, s, CH 3 ), 0.98 <lb/>(3H, s, CH 3 ), 1.04 (3H, s, CH 3 ), 1.68 (3H, s, CH 3 ), 1.85 <lb/>(1H, m, OH), 2.00 (3H, s, COCH 3 ), 2.54 (1H, m, H-19), <lb/>3.27 (1H, m, OH), 3.39 (1H, m, OH), 3.44 (1H, m, OH), <lb/>3.71 (1H, m, CH-sugar), 3.85 (1H, m, CH-sugar), 4.03 (1H, <lb/>d, J = 10.8 Hz, H-28), 4.37 (1H, m, H-3), 4.55 (1H, d, J = <lb/>10.8 Hz, H-28), 4.59 (1H, s, H-29), 4.63 (1H, m, CH-sugar), <lb/>4.73 (1H, s, H-29), 5.20 (1H, d, J = 5.4 Hz, CH-sugar), 5.35 <lb/>(1H, d, J = 5.4 Hz, CH-sugar), 5.46 (1H, d, J = 5.4 Hz, CH-<lb/>sugar), 5.61 (1H, d, J = 5.4 Hz, CH-sugar), 9.08 (1H, s, <lb/>CH-triazole); 13 C NMR (150 MHz, DMSO-d 6 ): δ 15.0, <lb/>16.1, 16.3, 16.9, 18.2, 19.3, 20.8, 21.5, 23.8, 25.2, 27.1, <lb/>28.1, 29.4, 29.6, 34.0, 34.6, 37.1, 37.6, 37.8, 38.2, 39.6, <lb/>42.8, 46.8, 47.5, 48.7, 50.0, 55.0, 61.2, 62.6, 69.9, 72.4, <lb/>77.2, 79.6, 80.6, 88.3, 110.5, 129.1, 139.2, 150.3, 160.9, <lb/>170.6; HRAPCIMS m/z (neg): 740.4480 C 41 H 62 N 3 O 9 <lb/>(calcd. 740.4486). <lb/>3-Acetyl-28-(1-ethylacetyl-1H-1,2,3-triazol-4-yl)carbonylbe-<lb/>tulin (5g) Yield 80%; m.p. 221-224 °C; IR (KBr) ν max <lb/>2945, 1732, 1544, 1465, 1247-1213 cm -1 ; 1 H NMR <lb/>(600 MHz, CDCl 3 ): δ 0.85 (3H, s, CH 3 ), 0.86 (3H, s, CH 3 ), <lb/>0.88 (3H, s, CH 3 ), 0.99 (3H, s, CH 3 ), 1.08 (3H, s, CH 3 ), <lb/>1.34 (3H, t, J = 7.2 Hz, CH 3 ), 1.68 (3H, s, CH 3 ), 2.07 (3H, <lb/>s, COCH 3 ), 2.53 (1H, m, H-19), 4.18 (1H, d, J = 10.8 Hz, <lb/>H-28), 4.32 (2H, q, J = 7.2 Hz, OCH 2 ), 4.48 (1H, m, H-3), <lb/>4.58 (1H, d, J = 10.8 Hz, H-28), 4.63 (1H, s, H-29), 4.73 <lb/>(1H, s, H-29), 5.24 (2H, s, CH 2 ), 8.24 (1H, s, CH-triazole); <lb/>13 <lb/>C NMR (150 MHz, CDCl 3 ): δ 14.1, 14.8, 16.1, 16.2, 16.5, <lb/>18.2, 20.8, 21.3, 23.7, 25.2, 27.1, 27.9, 29.6, 29.8, 34.1, <lb/>34.7, 37.1, 37.7, 37.8, 38.4, 40.9, 42.7, 46.7, 47.8, 48.9, <lb/>50.3, 51.0, 55.4, 62.8, 63.7, 80.9, 110.0, 128.7, 140.7, <lb/>150.1, 160.9, 165.7, 171.1; HRAPCIMS m/z (neg): <lb/>664.4329 C 39 H 58 N 3 O 6 (calcd. 664.4326). <lb/>3-Acetyl-28-[1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl]car-<lb/>bonylbetulin (5h) Yield 83%; m.p. 116-119 °C; IR (KBr) <lb/>ν max 3425, 2945, 1732, 1543, 1465, 1246-1199 cm -1 ; 1 H <lb/>NMR (600 MHz, DMSO-d 6 ): δ 0.80 (3H, s, CH 3 ), 0.81 (3H, <lb/>s, CH 3 ), 0.82 (3H, s, CH 3 ), 0.98 (3H, s, CH 3 ), 1.03 (3H, s, <lb/>CH 3 ), 1.09 (2H, m, CH 2 ), 1.67 (3H, s, CH 3 ), 2.02 (3H, s, <lb/>COCH 3 ), 2.51 (1H, m, H-19), 3.34 (2H, m, CH 2 ), 4.01 (1H, <lb/>d, J = 10.8 Hz, H-28), 4.38 (1H, m, H-3), 4.48 (2H, t, J = <lb/>7.2 Hz, CH 2 ), 4.54 (1H, d, J = 10.8 Hz, H-28), 4.59 (1H, s, <lb/>H-29), 4.73 (1H, s, H-29), 8.81 (1H, s, CH-triazole); 13 C <lb/>NMR (150 MHz, DMSO-d 6 ): δ 14.9, 16.1, 16.3, 16.9, 18.2, <lb/>19.2, 20.7, 21.5, 24.8, 25.1, 27.1, 28.1, 29.4, 29.6, 33.1, <lb/>34.0, 34.6, 37.1, 37.6, 37.8, 38.2, 40.9, 42.8, 46.8, 47.5, <lb/>47.6, 48.7, 50.0, 55.0, 57.8, 62.5, 80.4, 110.4, 129.7, 139.0, <lb/>150.3, 161.0, 170.6; HRAPCIMS m/z (neg): 636.4363 <lb/>C 38 H 58 N 3 O 5 (calcd. 636.4376). <lb/>2-Amino-3-[4-(3-acetyl-28-betulinylcarbonyl)-1H-1,2,3-tria-<lb/>zol-1-yl]propanoic acid (5i) Yield 45%; oil; IR (KBr) ν max <lb/>3444, 2956, 1732, 1602, 1458, 1246-1122 cm -1 ; 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ: 0.80 (3H, s, CH 3 ), 0.82 (3H, s, <lb/>CH 3 ), 0.86 (3H, s, CH 3 ), 0.92 (3H, s, CH 3 ), 1.01 (3H, s, <lb/>CH 3 ), 1.06 (1H, t, J = 7.2 Hz, CH), 1.67 (3H, s, CH 3 ), 2.00 <lb/>(3H, s, COCH 3 ), 2.52 (1H, m, H-19), 4.14 (1H, d, J = <lb/>10.8 Hz, H-28), 4.23 (2H, d, J = 7.2 Hz, CH 2 ), 4.37 (1H, m, <lb/>H-3), 4.55 (1H, d, J = 10.8 Hz, H-28), 4.58 (1H, s, H-29), <lb/>4.73 (1H, s, H-29), 8.62 (1H, s, CH-triazole); 13 C NMR <lb/>(150 MHz, DMSO-d 6 ): δ 14.9, 15.8, 16.1, 16.8, 18.3, 19.2, <lb/>19.6, 21.2, 22.9, 23.7, 26.8, 28.8, 30.3, 30.6, 30.8, 34.1, <lb/>34.5, 36.8, 37.2, 37.5, 38.5, 39.6, 42.8, 46.2, 47.0, 47.2, <lb/>48.6, 50.1, 54.3, 56.5, 67.8, 80.2, 110.0, 129.2, 132.1, <lb/>150.1, 161.0, 167.5; HRAPCIMS m/z (neg): 665.4269 <lb/>C 38 H 57 N 4 O 6 (calcd. 665.4278). <lb/>28-(1-Benzyl-1H-1,2,3-triazol-4-yl)carbonylbetulone (6a) <lb/>Yield 81%; m.p. 196-198 °C; IR (KBr) ν max 2963, 1738, <lb/>1700, 1539, 1465, 1261-1193 cm -1 ; 1 H NMR (600 MHz, <lb/>CDCl 3 ) δ: 0.94 (3H, s, CH 3 ), 1.02 (3H, s, CH 3 ), 1.05 (3H, s, <lb/>CH 3 ), 1.10 (3H, s, CH 3 ), 1.12 (3H, s, CH 3 ), 1.69 (3H, s, <lb/>CH 3 ), 2.52 (1H, m, H-19), 4.15 (1H, d, J = 10.8 Hz, H-28), <lb/>4.57 (1H, d, J = 10.8 Hz, H-28), 4.62 (1H, s, H-29), 4.72 <lb/>(1H, s, H-29), 5.60 (2H, s, CH 2 ), 7.31-7.33 (2H, m, H Ar ), <lb/>7.41-7.44 (3H, m, H Ar ), 7.97 (1H, s, CH-triazole); 13 C NMR <lb/>(150 MHz, CDCl 3 ): δ 14.7, 15.8, 15.9, 19.1, 19.6, 21.1, <lb/>21.3, 25.2, 25.6, 26.6, 27.1, 29.6, 29.8, 33.5, 34.2, 34.7, <lb/>36.9, 37.8, 39.6, 40.9, 42.8, 46.7, 47.4, 47.7, 48.8, 49.7, <lb/>54.5, 55.0, 63.5, 68.0, 110.0, 127.1, 128.2, 129.2, 129.3, <lb/>133.8, 140.6, 150.0, 161.2, 218.0; HRAPCIMS m/z (neg): <lb/>624.4171 C 40 H 54 N 3 O 3 (calcd. 624.4165). <lb/>28-[1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl]carbonylbetu-<lb/>lone (6b) Yield 73%; m.p. 220-223 °C; IR (KBr) ν max <lb/>3131, 2957, 1742, 1699, 1539, 1456, 1223-1198, 814 cm <lb/>-1 ; 1 H NMR (600 MHz, CDCl 3 ): δ 0.86 (3H, s, CH 3 ), 0.91 <lb/>(3H, s, CH 3 ), 0.92 (3H, s, CH 3 ), 0.95 (3H, s, CH 3 ), 1.02 <lb/>(3H, s, CH 3 ), 1.68 (3H, s, CH 3 ), 2.43 (1H, m, H-19), 4.05 <lb/>(1H, d, J = 10.8 Hz, H-28), 4.48 (1H, d, J = 10.8 Hz, H-28), <lb/>4.53 (1H, s, H-29), 4.63 (1H, s, H-29), 5.48 (2H, s, CH 2 ), <lb/>7.01-7.04 (2H, m, H Ar ), 7.23-7.36 (2H, m, H Ar ), 7.88 (1H, <lb/>s, CH-triazole); 13 C NMR (150 MHz, CDCl 3 ): δ 14.7, 15.8, <lb/>15.9, 19.2, 19.6, 21.1, 21.3, 25.2, 26.6, 27.1, 29.6, 29.8, <lb/>33.5, 34.2, 34.7, 36.9, 37.8, 39.6, 40.9, 42.8, 46.7, 47.4, <lb/>47.7, 48.8, 49.7, 53.7, 55.0, 63.6, 68.1, 110.0, 116.3, 116.5, <lb/></body>

			<page>2054 <lb/></page>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<body>126.2, 126.3, 130.2, 140.0, 150.0, 161.1, 218.0; HRAP-<lb/>CIMS m/z (neg): 642.4063 C 40 H 53 FN 3 O 3 (calcd. 642.4071). <lb/>28-[1-(4-Cyanobenzyl)-1H-1,2,3-triazol-4-yl]carbonylbetu-<lb/>lone (6c) Yield 57%; m.p. 211-214 °C; IR (KBr) ν max <lb/>3127, 2951, 2229, 1734,1705, 1525, 1457, 1243-1147 cm <lb/>-1 ; 1 H NMR (600 MHz, CDCl 3 ): δ 0.87 (3H, s, CH 3 ), 0.93 <lb/>(3H, s, CH 3 ), 0.96 (3H, s, CH 3 ), 1.02 (3H, s, CH 3 ), 1.03 <lb/>(3H, s, CH 3 ), 1.68 (3H, s, CH 3 ), 2.44 (1H, m, H-19), 4.07 <lb/>(1H, d, J = 10.8 Hz, H-28), 4.49 (1H, d, J = 10.8 Hz, 1H, <lb/>H-28), 4.54 (1H, s, H-29), 4.63 (1H, s, H-29), 5.59 (2H, s, <lb/>CH 2 ), 7.31 (2H, d, J = 8.4 Hz, H Ar ), 7.63 (2H, d, J = <lb/>8.4 Hz, H Ar ), 7.96 (1H, s, CH-triazole); 13 C NMR <lb/>(150 MHz, CDCl 3 ): δ 14.7, 15.8, 15.9, 19.1, 19.6, 21.1, <lb/>21.3, 23.7, 25.2, 26.6, 27.1, 29.6, 29.8, 33.5, 34.2, 34.7, <lb/>36.9, 37.8, 39.6, 40.9, 42.8, 46.7, 47.4, 47.7, 48.8, 49.7, <lb/>53.7, 55.0, 63.7 110.1, 113.3, 117.9, 127.4, 128.5, 133.1, <lb/>138.9, 141.0, 149.9, 160.9, 218.1; HRAPCIMS m/z (neg): <lb/>649.4095 C 41 H 53 N 4 O 3 (calcd. 649.4118). <lb/>28-(1-Phenylthiomethyl-1H-1,2,3-triazol-4-yl)carbonylbetu-<lb/>lone (6d) Yield 87%; m.p. 188-191 °C; IR (KBr) ν max <lb/>3132, 2960, 1734, 1705, 1521, 1456, 1241-1196 cm -1 ; 1 H <lb/>NMR (600 MHz, CDCl 3 ): δ 0.96 (3H, s, CH 3 ), 1.03 (3H, s, <lb/>CH 3 ), 1.05 (3H, s, CH 3 ), 1.09 (3H, s, CH 3 ), 1.11 (3H, s, <lb/>CH 3 ), 1.69 (3H, s, CH 3 ), 2.53 (1H, m, H-19), 4.15 (1H, d, J <lb/>= 10.8 Hz, H-28), 4.57 (1H, d, J = 10.8 Hz, H-28), 4.63 <lb/>(1H, s, H-29), 4.74 (1H, s, H-29), 5.69 (2H, s, CH 2 ), 7.34-<lb/>7.37 (5H, m, H Ar ), 8.06 (1H, s, CH-triazole); 13 C NMR <lb/>(150 MHz, CDCl 3 ): δ 14.7, 15.8, 15.9, 19.1, 19.6, 21.1, <lb/>21.3, 25.2, 25.6, 26.6, 27.1, 29.6, 29.8, 33.5, 34.2, 34.7, <lb/>36.9, 37.8, 39.6, 40.9, 42.8, 46.7, 47.4, 47.7, 48.8, 49.7, <lb/>54.3, 55.0, 63.6, 68.0, 110.0, 126.8, 129.1, 129.7, 131.3, <lb/>132.4, 150.0, 160.9, 218.1; HRAPCIMS m/z (neg): <lb/>656.3895 C 40 H 54 N 3 O 3 S (calcd. 656.3886). <lb/>28-[1-(3&apos;-Deoxythymidine-5&apos;-yl)-1H-1,2,3-triazol-4-yl]carbo-<lb/>nylbetulone (6e) Yield 73%; m.p. 199-202 °C; IR (KBr) <lb/>ν max 3447, 3068, 2945, 1729, 1697, 1541, 1458, <lb/>1226-1163 cm -1 ; 1 H NMR (600 MHz, DMSO-d 6 ): δ 0.88 <lb/>(3H, s, CH 3 ), 0.94 (3H, s, CH 3 ), 0.99 (3H, s, CH 3 ), 1.02 <lb/>(3H, s, CH 3 ), 1.05 (3H, s, CH 3 ), 1.68 (3H, s, CH 3 ), 1.74 <lb/>(3H, s, CH 3 -AZT), 2.51 (1H, m, AZT), 2.67 (1H, m, H-19), <lb/>3.65-3.70 (2H, m, AZT), 4.04 (1H, d, J = 10.8 Hz, H-28), <lb/>4.27 (1H, t, J = 4.8 Hz, AZT), 4.55 (1H, d, J = 10.8 Hz, H-<lb/>28), 4.58 (1H, s, H-29), 4.74 (1H, s, H-29), 5.27 (1H, t, J = <lb/>4.8 Hz, AZT), 5.46 (1H, m, AZT), 6.44 (1H, t, J = 6.6 Hz, <lb/>AZT), 7.82 (1H, s, AZT), 8.32 (1H, s, CH-triazole), 9.02 <lb/>(1H, s, NH-AZT); 13 C NMR (150 MHz, DMSO-d 6 ): δ 12.7, <lb/>14.9, 15.8, 15.9, 16.1, 19.3, 19.6, 21.2, 21.3, 25.3, 26.8, <lb/>27.1, 29.4, 29.6, 33.4, 34.1, 34.6, 36.8, 37.6, 37.7, 39.3, <lb/>39.6, 42.8, 46.8, 47.0, 47.5, 48.6, 49.4, 54.3, 55.6, 60.2, <lb/>61.1, 62.7, 79.6, 84.3, 84.7, 110.1, 110.5, 129.3, 136.7, <lb/>139.3, 150.3, 150.9, 160.9, 164.2, 217.0; HRAPCIMS m/z <lb/>(neg): 758.4484 C 43 H 60 N 5 O 7 (calcd. 758.4493). <lb/>28-[1-(1-Deoxy-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl] <lb/>carbonylbetulone (6f) Yield 74%; m.p. 187-189 °C; IR <lb/>(KBr) ν max 3419, 2939, 1732, 1701, 1541, 1458, <lb/>1232-1190 cm -1 ; 1 H NMR (600 MHz, DMSO-d 6 ): δ 0.88 <lb/>(3H, s, CH 3 ), 0.94 (3H, s, CH 3 ), 0.99 (3H, s, CH 3 ), 1.02 <lb/>(3H, s, CH 3 ), 1.07 (3H, s, CH 3 ), 1.68 (3H, s, CH 3 ), 1.86 <lb/>(1H, m, OH), 2.56 (1H, m, H-19), 3.27 (1H, m, OH), 3.40 <lb/>(1H, m, OH), 3.45 (1H, m, OH), 3.71 (1H, m, CH-sugar), <lb/>3.85 (1H, m, CH-sugar), 4.04 (1H, d, J = 10.8 Hz, H-28), <lb/>4.56 (1H, d, J = 10.8 Hz, H-28), 4.59 (1H, s, H-29), 4.63 <lb/>(1H, m, CH-sugar), 4.74 (1H, s, H-29), 5.20 (1H, d, J = <lb/>5.4 Hz, CH-sugar), 5.34 (1H, d, J = 5.4 Hz, CH-sugar), 5.45 <lb/>(1H, d, J = 5.4 Hz, CH-sugar), 5.62 (1H, d, J = 5.4 Hz, CH-<lb/>sugar), 9.08 (1H, s, CH-triazole); 13 C NMR (150 MHz, <lb/>DMSO-d 6 ): δ 14.9, 15.8, 16.1, 19.3, 19.6, 21.2, 21.3, 25.2, <lb/>26.8, 27.1, 29.4, 29.6, 33.4, 34.1, 34.6, 36.8, 37.1, 39.3, <lb/>42.8, 46.8, 47.0, 47.5, 48.7, 49.4, 54.3, 61.2, 62.6, 69.9, <lb/>72.4, 77.2, 79.6, 80.6, 88.3, 110.5, 129.1, 139.2, 150.3, <lb/>160.9, 218.0; HRAPCIMS m/z (neg): 696.4220 <lb/>C 39 H 58 N 3 O 8 (calcd. 696.4224). <lb/>28-(1-Ethylacetyl-1H-1,2,3-triazol-4-yl)carbonylbetulone <lb/>(6g) Yield 79%; m.p. 97-99 °C; IR (KBr) ν max 3147, <lb/>2945, 1755, 1705, 1541, 1458, 1211-1111 cm -1 ; 1 H NMR <lb/>(600 MHz, CDCl 3 ): δ 0.88 (3H, s, CH 3 ), 0.93 (3H, s, CH 3 ), <lb/>0.95 (3H, s, CH 3 ), 1.00 (3H, s, CH 3 ), 1.03 (3H, s, CH 3 ), <lb/>1.26 (3H, t, J = 7.2 Hz, CH 3 ), 1.68 (3H, s, CH 3 ), 2.45 (1H, <lb/>m, H-19), 4.10 (1H, d, J = 10.8 Hz, H-28), 4.23 (2H, q, J = <lb/>7.2 Hz, OCH 2 ), 4.51 (1H, d, J = 10.8 Hz, H-28), 4.54 (1H, <lb/>s, H-29), 4.65 (1H, s, H-29), 5.15 (2H, s, CH 2 ), 8.16 (1H, s, <lb/>CH-triazole); 13 C NMR (150 MHz, CDCl 3 ): δ 14.2, 14.7, <lb/>15.9, 19.6, 21.1, 21.3, 25.2, 26.6, 27.1, 29.6, 29.8, 33.5, <lb/>34.2, 34.7, 36.9, 37.8, 39.6, 40.9, 42.8, 46.7, 47.4, 47.7, <lb/>48.8, 49.7, 51.0, 55.0, 60.4, 62.8, 63.6, 110.0, 128.7, 140.7, <lb/>150.1, 160.9, 165.7, 171.2, 218.1; HRAPCIMS m/z (neg): <lb/>620.4049 C 37 H 54 N 3 O 5 (calcd. 620.4063). <lb/>28-[1-(3-Hydroxypropyl)-1H-1,2,3-triazol-4-yl]carbonylbetu-<lb/>lone (6h) Yield 78%; m.p. 197-199 °C; IR (KBr) ν max <lb/>3404, 2960, 1735, 1703, 1543, 1458, 1261-1223 cm -1 ; 1 H <lb/>NMR (600 MHz, DMSO-d 6 ): δ 0.88 (3H, s, CH 3 ), 0.94 (3H, <lb/>s, CH 3 ), 0.99 (3H, s, CH 3 ), 1.00 (3H, s, CH 3 ), 1.05 (3H, s, <lb/>CH 3 ), 1.10 (2H, m, CH 2 ), 1.67 (3H, s, CH 3 ), 2.52 (1H, m, <lb/>H-19), 3.38 (2H, m, CH 2 ), 4.02 (1H, d, J = 10.8 Hz, H-28), <lb/>4.48 (2H, t, J = 7.2 Hz, CH 2 ), 4.55 (1H, d, J = 10.8 Hz, H-<lb/>28), 4.59 (1H, s, H-29), 4.74 (1H, s, H-29), 8.81 (1H, s, CH-<lb/>triazole); 13 C NMR (150 MHz, DMSO-d 6 ): δ 14.9, 15.8, <lb/>16.1, 19.2, 19.5, 21.2, 21.3, 25.2, 26.8, 27.1, 29.4, 29.6, <lb/>33.1, 33.4, 34.1, 34.6, 36.8, 37.7, 39.3, 42.8, 46.8, 47.0, <lb/>47.5, 47.6, 48.6, 49.3, 54.3, 57.8, 62.5, 79.6, 110.5, 129.7, <lb/></body>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<page>2055 <lb/></page>

			<body>139.0, 150.3 161.0, 217.0; HRAPCIMS m/z (neg): <lb/>592.4131 C 36 H 54 N 3 O 4 (calcd. 592.4114). <lb/>2-Amino-3-[4-(3-acetyl-28-betulonylcarbonyl)-1H-1,2,3-tria-<lb/>zol-1-yl]propanoic acid (6i) Yield 48%; 163-166 °C; IR <lb/>(KBr) ν max 3479, 2956, 1732, 1705, 1606, 1456, <lb/>1280-1223 cm -1 ; 1 H NMR (600 MHz, DMSO-d 6 ) δ: 0.85 <lb/>(3 H s, CH 3 ), 0.89 (3H, s, CH 3 ), 0.98 (3H, s, CH 3 ), 1.02 <lb/>(3H, s, CH 3 ), 1.04 (3H, s, CH 3 ), 1.07 (1H, t, J = 7.2 Hz, <lb/>CH), 1.67 (3H, s, CH 3 ), 2.51 (1H, m, H-19), 4.12 (1H, d, J <lb/>= 10.8 Hz, H-28), 4.21 (2H, d, J = 7.2 Hz, CH 2 ), 4.56 (1H, <lb/>d, J = 10.8 Hz, H-28), 4.59 (1H, s, H-29), 4.74 (1H, s, H-<lb/>29), 8.62 (1H, s, CH-triazole); 13 C NMR (150 MHz, <lb/>DMSO-d 6 ): δ 14.3, 15.0, 16.1, 16.3, 16.9, 21.5, 22.9, 23.7, <lb/>28.1, 28.8, 30.2, 37.1, 37.8, 38.5, 39.5, 40.8, 42.8, 67.9, <lb/>80.4, 110.0, 129.1, 132.1, 132.2, 150.1, 167.5, 217.1; <lb/>HRAPCIMS m/z (neg): 621.4050 C 36 H 53 N 4 O 5 (calcd. <lb/>621.4015). <lb/>3-Methyl-3-[4-(28-betulonylcarbonyl)-1H-1,2,3-triazol-1-yl] <lb/>butyric acid (6j) Yield 54%; m.p. 246-249 °C; IR (KBr) <lb/>ν max 3446, 2945, 1732, 1709, 1616, 1456, 1280-1211 cm <lb/>-1 ; 1 H NMR (600 MHz, DMSO-d 6 ) δ: 0.72 (3H, s, CH 3 ), <lb/>0.87 (3H, s, CH 3 ), 0.96 (3H, s, CH 3 ), 1.00 (3H, d, J = <lb/>6.6 Hz, CH 3 ), 1.01 (3H, s, CH 3 ), 1.04 (3H, s, CH 3 ), 1.08 <lb/>(3H, d, J = 6.6 Hz, CH 3 ), 1.68 (3H, s, CH 3 ), 2.43 (1H, m, <lb/>CH), 2.53 (1H, m, H-19), 4.03 (1H, d, J = 10.8 Hz, H-28), <lb/>4.28 (1H, m, CHCOOH), 4.55 (1H, d, J = 10.8 Hz, H-28), <lb/>4.64 (1H, s, H-29), 4.74 (1H, s, H-29), 8.76 (1H, s, CH-<lb/>triazole); 13 C NMR (150 MHz,, DMSO-d 6 ) δ: 14.3, 14.6, <lb/>14.9, 15.8, 16.0, 16.1, 18.9, 19.2, 19.6, 19.9, 21.2, 25.2, <lb/>26.8, 27.1, 29.5, 29.7, 30.8, 33.4, 34.1, 36.8, 37.7, 39.3, <lb/>40.8, 42.8, 46.8, 47.0, 47.5, 48.6, 49.3, 54.3, 62.6, 79.7, <lb/>110.5, 129.4, 138.7, 150.3, 161.3, 217.1; HRAPCIMS m/z <lb/>(neg): 535.3878 C 35 H 51 O 4 (calcd. 535.3865). <lb/>Biological study <lb/>Cells <lb/>The triterpenes were evaluated for their cytotoxic activity <lb/>towards three human cancer cell lines: amelanotic mela-<lb/>noma C-32 (ATCC, Rockville, USA), ductal carcinoma <lb/>T47D (ATCC, Rockville, USA) and glioblastoma SNB-19 <lb/>(DSMZ, Braunschweig, Germany). The cells were seeded <lb/>in 96-well plates (Nunc Thermo Fisher Scientific, Waltham, <lb/>USA) at a density of 5 × 10 3 cells per well and maintained <lb/>for 24 h at 37 °C in a humid atmosphere saturated with 5% <lb/>CO 2 . All cancer cell lines were cultured in DMEM (Lonza, <lb/>Basel, Switzerland) growth medium containing 10% fetal <lb/>bovine serum (FBS) (Biological Industries, Cromwell, <lb/>USA), penicillin (10,000 U/mL) and streptomycin(10 mg/ <lb/>mL) (Lonza, Basel, Switzerland). <lb/>WST-1 assay <lb/>A WST-1 assay (Roche Diagnostics GmbH, Mannheim, <lb/>Germany) was used for the evaluate of cytotoxicity against <lb/>the tested human cancer cell lines. The WST-1 assay was <lb/>carried out after 72 h incubation of the cells with con-<lb/>centrations ranging from 1 to 100 µg/mL of the tested <lb/>compounds. The WST-1 tetrazolium salt [sodium 2-(4-<lb/>iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-<lb/>tetrazolium] is reduced by mitochondrial dehydrogenases of <lb/>viable cells to water-soluble formazan. The amount of for-<lb/>mazan produced by viable cells was quantified by measur-<lb/>ing the absorbance (λ = 450 nm). The anticancer activity of <lb/>triterpenes were expressed as an IC 50 in µM (Table 2). <lb/>Lipophilicity studies <lb/>The theoretical lipophilicity parameters of triazoles 5a-i and <lb/>6a-j were calculated using the commercially available <lb/>ALOGPS 2.1 software program (Tetko et al. 2005) (Table <lb/>3). <lb/>Results and discussion <lb/>Chemistry <lb/>The synthesis of triazoles was started from betulin 1 and 3-<lb/>acetylbetulin 2 (Fig. 1). Acetylation of betulin 1 at the C-3 <lb/>and C-28 positions with acetic anhydride in the presence of <lb/>4-dimethylaminopyridine in pyridine gave betulin 3,28-<lb/>diacetate. A selective hydrolysis of betulin 3,28-diacetate at <lb/>C-28 <lb/>position <lb/>(MeOH/NaOH/THF) <lb/>afforded <lb/>3-<lb/>acetylobetulin 2 with a quantitative yield (Thibeault et al. <lb/>2007; Santos et al. 2010). <lb/>Subsequently, triterpenes 1-2 were used to prepare the <lb/>propynoylated derivatives 3-4 according to our published <lb/>procedures (Boryczka et al. 2013). The triazoles 5a-i and <lb/>6a-j were obtained by CuAAC reactions of acetylenic esters <lb/>with various organic azides in toluene with yields in the <lb/>range of 45-87%. Synthesis of triazoles 5a-i and 6a-j was <lb/>depicted in Scheme 1. New compounds were purified by <lb/>column chromatography on silica gel in CHCl 3 -EtOH or <lb/>CH 2 Cl 2 -EtOH with various ratios. The chemical char-<lb/>acterization of all derivatives was carried out by 1 H-, 13 C-<lb/>NMR, IR spectroscopies, and HRMS spectra. <lb/>In the 1 H NMR spectra of the triazoles 5a-d and 6a-d, <lb/>singlets of methylene group were observed at δ 5.48-5.69, <lb/>which suggests the presence of a bond between C-4 (aryl <lb/>group) and N-1 of the triazole ring. The signals in the range <lb/>of δ 7.01-7.72 were assigned to the aromatic protons of the <lb/>aryl group of derivatives 5a-d and 6a-d. Additionally, for <lb/>all derivatives 5a-i and 6a-j, signals at δ 7.96-9.08 were <lb/></body>

			<page>2056 <lb/></page>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<body>Table 2 Anticancer activity (IC 50 ) of acetylenic esters 3-4, triazoles of triterpenes 5a-i and 6a-j and cisplatin as a reference compound against the <lb/>tested human cancer cell lines <lb/></body>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<page>2057 <lb/></page>

			<body>observed, corresponding to triazolyl protons in the 1,4-<lb/>disubstituted triazole ring. <lb/>Analysis of the 13 C NMR spectra of triazoles 5a-i and <lb/>6a-j showed that the signals of acetyl and carbonyl groups <lb/>are located at 167.5-171.1 p.p.m. and 217.0-218.1 p.p.m., <lb/>respectively. <lb/>The IR spectra of new triazoles 5a-i and 6a-j showed <lb/>characteristic absorption bands at 1527-1616 cm -1 and <lb/>1456-1458 cm -1 , which were attributed to the C=N and the <lb/>N=N stretching vibrations of the triazole ring, respectively. <lb/>The HRMS negative mode was applied to identify all <lb/>new compounds. In the mass spectra of triterpenes 3, 5a-i, <lb/></body>

			<page>2058 <lb/></page>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<body>and 6a-j signals based on ions [M-H] -were observed. <lb/>These signals were corresponding to the calculated values. <lb/>Biological study <lb/>The triazole derivatives of 3-acetylbetulin and betulone <lb/>were evaluated in vitro for their anticancer activity using a <lb/>WST-1 assay against three human cancer cell lines: ame-<lb/>lanotic melanoma C-32, ductal carcinoma T47D and glio-<lb/>blastoma SNB-19. Cisplatin was used as a positive control. <lb/>The results of the anticancer activity tests of the studied <lb/>compounds are reported in Table 2 as IC 50 (µM). <lb/>As shown in Table 2, the lowest anticancer activity (IC 50 <lb/>7.56-83.88 µM) of targeted triazoles was observed in the <lb/>case of the T47D ductal carcinoma cell line. In the tested <lb/>group of triazoles, derivative 6i exhibited a highest antic-<lb/>ancer activity (IC 50 7.56 µM) against the T47D cells, when <lb/>compared to the positive control. <lb/>For triazoles of 3-acetylbetulin 5a-i, the rank order of the <lb/>anticancer activity towards the C-32 cell line is as follows: <lb/>5g &gt; 5b &gt; 5a &gt; 5d &gt; 5h &gt; 5i &gt; 5f &gt; 5e &gt; 5c. The compound <lb/>5g containing a 1-ethylacetyl moiety in triazole ring had the <lb/>same anticancer activity against the C-32 cell line as the <lb/>reference cisplatin (IC 50 0.57 µM). Moreover, triazoles 5c, <lb/>6a, and 6g had no anticancer activity towards C-32 cell line <lb/>in the applied concentration range. <lb/>According to our studies, compounds 5b, 5g, 6b, and 6e <lb/>showed a significant activity against human glioblastoma <lb/>SNB-19 cell line, with IC 50 values from 0.17 to 0.85 µM. <lb/>The triazole 6e bearing a 3&apos;-deoxythymidine-5&apos;-yl moi-<lb/>ety showed the highest activity in the tested group of <lb/>compounds against SNB-19 cells, with IC 50 value of <lb/>0.17 µM. <lb/>Our studies suggest, that the introduction of acetyl or <lb/>carbonyl group at the C-3 position of triazole derivatives of <lb/>triterpenes afforded compounds having a higher anticancer <lb/>activity against amelanotic melanoma C-32 cell line. <lb/>Additionally, the compounds 5f and 6f containing the 1-<lb/>deoxy-β-D-glucopyranosyl substituted triazole ring had a <lb/>better activity than their parent 3-hydroxyl substituted <lb/>analogs against C-32, T47D, and SNB-19 cell lines <lb/>(Bębenek et al. 2017). <lb/>Table 3 The values of calculated lipophilicity parameters of compound 5a-i and 6a-j <lb/>Compound <lb/>ALOGPs <lb/>AC logP <lb/>ALOGP <lb/>MLOGP <lb/>XLOGP2 <lb/>XLOGP3 <lb/>5a <lb/>7.76 <lb/>9.09 <lb/>9.56 <lb/>7.29 <lb/>11.43 <lb/>11.87 <lb/>5b <lb/>6.97 <lb/>7.00 <lb/>9.13 <lb/>7.63 <lb/>10.63 <lb/>10.95 <lb/>5c <lb/>6.91 <lb/>7.27 <lb/>8.81 <lb/>6.78 <lb/>10.33 <lb/>10.50 <lb/>5d <lb/>7.19 <lb/>9.60 <lb/>9.52 <lb/>7.44 <lb/>11.03 <lb/>11.43 <lb/>5e <lb/>5.54 <lb/>4.70 <lb/>6.46 <lb/>4.98 <lb/>7.45 <lb/>8.30 <lb/>5f <lb/>4.54 <lb/>3.99 <lb/>5.19 <lb/>3.99 <lb/>6.85 <lb/>6.96 <lb/>5g <lb/>6.26 <lb/>5.78 <lb/>7.61 <lb/>6.15 <lb/>9.03 <lb/>9.58 <lb/>5h <lb/>5.85 <lb/>5.75 <lb/>6.87 <lb/>5.98 <lb/>8.55 <lb/>8.80 <lb/>5i <lb/>2.66 <lb/>3.80 <lb/>6.22 <lb/>3.03 <lb/>5.44 <lb/>5.53 <lb/>6a <lb/>6.62 <lb/>7.13 <lb/>8.51 <lb/>6.78 <lb/>9.26 <lb/>9.89 <lb/>6b <lb/>6.50 <lb/>7.19 <lb/>8.72 <lb/>7.14 <lb/>9.43 <lb/>9.99 <lb/>6c <lb/>6.58 <lb/>6.94 <lb/>8.39 <lb/>6.39 <lb/>8.99 <lb/>9.61 <lb/>6d <lb/>6.78 <lb/>9.28 <lb/>9.10 <lb/>7.05 <lb/>9.69 <lb/>10.54 <lb/>6e <lb/>5.04 <lb/>4.38 <lb/>6.04 <lb/>4.56 <lb/>6.11 <lb/>7.41 <lb/>6f <lb/>4.16 <lb/>3.67 <lb/>4.77 <lb/>3.56 <lb/>5.50 <lb/>6.07 <lb/>6g <lb/>5.90 <lb/>5.45 <lb/>7.20 <lb/>5.72 <lb/>7.68 <lb/>8.69 <lb/>6h <lb/>5.54 <lb/>5.43 <lb/>6.45 <lb/>5.57 <lb/>7.20 <lb/>7.91 <lb/>6i <lb/>2.37 <lb/>3.47 <lb/>5.80 <lb/>2.59 <lb/>4.10 <lb/>4.64 <lb/>6j <lb/>6.21 <lb/>6.00 <lb/>7.82 <lb/>5.90 <lb/>8.12 <lb/>9.36 <lb/>Fig. 1 Chemical structure of betulin 1 and 3-acetylbetulin 2 <lb/></body>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<page>2059 <lb/></page>

			<body>The lipophilicity is one of the important physicochemical <lb/>parameters in drug development (Andric and Héberger <lb/>2015). A lipophilicity study of the tested triazoles was <lb/>carried out using the ALOGPS 2.1 software program. The <lb/>predicted log P values were calculated according to the <lb/>molecular structures of triazoles 5a-i and 6a-j using six <lb/>computational methods (ALOGPs, AC logP, ALOGP, <lb/>MLOGP, XLOGP2, and XLOGP3). Considering two tria-<lb/>zoles of betulone 6d and 6e, it was observed that their <lb/>cytotoxic activity increased with the decreasing value of <lb/>theoretical log P. <lb/>Conclusion <lb/>In conclusion, on the basis of the CuAAC reaction, a series <lb/>of new derivatives of 3-acetylbetulin and betulone bearing <lb/>1,2,3-triazole moiety has been synthesized. The anticancer <lb/>activity of the triazoles and cisplatin was tested against the <lb/>C-32, T47D and SNB-19 cancer cell lines using the WST-1 <lb/>assay. The triazole 6e with 3&apos;-deoxythymidine-5&apos;-yl sub-<lb/>stituent proved to be a potent cytotoxic agent with IC 50 <lb/>value of 0.17 µM in the case of the human glioblastoma <lb/>SNB-19 cell line. Morever, the triazole 6e can be con-<lb/>sidered as a promising candidate for anticancer therapy. <lb/></body>

			<div type="acknowledgement">Acknowledgements This work was supported by the Medical Uni-<lb/>versity of Silesia in Katowice, Poland. Grant No KNW-1-015/K/7/0. <lb/>Compliance with ethical standards <lb/></div>

			<div type="annex">Conflict of interest The authors declare that they have no conflict of <lb/>interest. <lb/>Open Access This article is distributed under the terms of the Creative <lb/>Commons Attribution 4.0 International License (http://crea <lb/>tivecommons.org/licenses/by/4.0/), which permits use, duplication, <lb/>adaptation, distribution, and reproduction in any medium or format, as <lb/>long as you give appropriate credit to the original author(s) and the <lb/>source, provide a link to the Creative Commons license, and indicate if <lb/>changes were made. <lb/></div>

			<listBibl>References <lb/>Andrić F, Héberger K (2015) Towards better understanding of lipo-<lb/>philicity: assessment of in silico and chromatographic log P <lb/>measures for pharmaceutically important compounds by non-<lb/>parametric rankings. J Pharm Biomed Anal 115:183-191 <lb/>Bębenek E, Jastrzębska M, Kadela-Tomanek M, Chrobak E, Orze-<lb/>chowska B, Zwolińska K, Latocha M, Mertas A, Czuba Z, <lb/>Boryczka S (2017) Novel triazole hybrids of betulin: synthesis <lb/>and biological activity profile. Molecules 22:1876-1892 <lb/>Bębenek E, Kadela-Tomanek M, Chrobak E, Wietrzyk J, Sadowska J, <lb/>Boryczka (2016) New acetylenic derivatives of betulin and <lb/>betulone, synthesis and cytotoxic activity. Med Chem Res <lb/>26:1-8 <lb/>Bonacorso HG, Moraes MC, Wiethan CW, Luz FM, Meyer AR, <lb/>Zanatta N, Martins MAP (2013) Synthesis of 1H-1,2,3-triazoles-<lb/>Rufinamide analogs by 1,3-dipolar cycloaddition and ele-<lb/>trocyclization reactions of trifluoroacetyl enolethers under ther-<lb/>mal solventless conditions. J Flu Chem 156:112-119 <lb/>Scheme 1 Synthesis of triazole derivatives 5a-i and 6a-j. Reagents and conditions: organic azide (RN 3 ), CuI, reflux, 72 h <lb/></listBibl>

			<page>2060 <lb/></page>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<listBibl>Boryczka S, Bębenek E, Wietrzyk J, Kempińska K, Jastrzębska M, <lb/>Kusz J, Nowak M (2013) Synthesis, structure and cytotoxic <lb/>activity of new acetylenic derivatives of betulin. Molecules <lb/>18:4526-4543 <lb/>Bräse S, Friedrich A, Gartner M M, Schröder T (2008) Cycloaddition <lb/>reactions of azides including bioconjugation. Top Heterocycl <lb/>Chem 12:45-115 <lb/>Dheer D, Singh V, Shankar R (2017) Medicinal attributes of 1,2,3-<lb/>triazoles: current developments. Bioorg Chem 71:30-54 <lb/>He Y-W, Dong C-Z, Zhao J-Y, Ma L-L, Li Y-H, Aisa HA (2014) <lb/>1,2,3-Triazole-containing derivatives of rupestonic acid: click-<lb/>chemical synthesis and antiviral activities against influenza <lb/>viruses. Eur J Med Chem 76:245-255 <lb/>Khan I, Guru SK, Rath SK, Chinthakindi PK, Singh B, Koul S, <lb/>Bhushan S, Sangwan PL (2016) A novel triazole derivative of <lb/>betulinic acid induces extrinsic and intrinsic apoptosis in human <lb/>leukemia HL-60 cells. Eur J Med Chem 108:104-116 <lb/>Majeed R, Sangwan PL, Chinthakindi PK, Khan I, Dangroo NA, <lb/>Thota N, Hamid A, Sharma PR, Saxena AK, Koul S (2013) <lb/>Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-tria-<lb/>zoles as potential apoptotic agents. Eur J Med Chem 63:782-792 <lb/>Marciniec K, Latocha M, Kurczab R, Boryczka S (2017) Synthesis <lb/>and anticancer activity evaluation of a quinoline-based 1,2,3-<lb/>triazoles. Med Chem Res 26:2432-2442 <lb/>Rostovtsev HV, Green LG, Fokin VV, Sharpless KB (2002) A step-<lb/>wise huisgen cycloaddition process: copper (I)-catalyzed regio-<lb/>selective &quot;ligation&quot; of azides and terminal alkynes. Angew Chem <lb/>Int Ed Engl 41:2596-2599 <lb/>Santos RC, Salvador JAR, Marín S, Cascate M, Moreira JN, Dini TCP <lb/>(2010) Synthesis and structure-activity relationship study of <lb/>novel cytotoxic carbamate and N-acylheterocyclic bearing deri-<lb/>vatives of betulin and betulinic acid. Bioorganic Med Chem <lb/>18:4385-4396 <lb/>Spivak AY, Gubaidullin RR, Galimshina ZR, Nedopekina DA, Odi-<lb/>nokov VN (2016) Effective synthesis of novel C(2)-propargyl <lb/>derivatives of betulinic and ursolic acids and their conjugation <lb/>with β-D-glucopyranoside azides via click chemistry. Tetra-<lb/>hedron 71:1249-1256 <lb/>Suman P, Patel A, Solano L, Jampana G, Gardner ZS, Holt CM, <lb/>Jonnalagadda SC (2016) Synthesis and cytotoxicity of Baylis-<lb/>Hillman template derived betulinic acid-triazole conjugates. Tet-<lb/>rahedron 73:4214-4226 <lb/>Tetko IV, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, <lb/>Palyulin VA, Radchenko EV, Zefirov NS, Makarenko AS, Tan-<lb/>chuk VY, Prokopenko VV (2005) Virtual computational chem-<lb/>istry laboratory-design and description. J Comput Aid Mol Des <lb/>19:453-463 <lb/>Thibeault D, Gauthier C, Legault J, Bouchard J, Dufour P, Pichette A <lb/>(2007) Synthesis and structure-activity relationship study of <lb/>cytotoxic germanicane -and lupane-type 3β-O-monodesmosidic <lb/>saponins starting from betulin. Bioorg Med Chem 15:6144-6157 <lb/>Torne CW, Christensen C, Meldal M (2002) Peptidotriazoles on solid <lb/>phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-<lb/>dipolar cycloadditions of terminal alkynes to azides. J Org Chem <lb/>67:3057-3064 <lb/>Totobenazara J, Anthony J, Burke AJ (2015) New click-chemistry <lb/>methods for 1,2,3-triazoles synthesis: recent advances and <lb/>applications. Tetrahedron Lett 56:2853-2859 <lb/>Wang X-L, Wan K, Zhou C-H (2010) Synthesis of novel <lb/>sulfanilamide-derived 1,2,3-triazoles and their evaluation for <lb/>antibacterial and antifungal activities. Eur J Med Chem <lb/>45:4631-4639 <lb/>Wei J, Chen J, Xu J, Cao L, Deng H, Sheng W, Zhang H, Cao W <lb/>(2012) Scope and regioselectivity of the 1,3-dipolar cycloaddition <lb/>of azides with methyl 2-perfluoroalkynoates for an easy, metal-<lb/>free route toperfluoroalkylated 1,2, 3-triazoles. J Flu Chem <lb/>133:146-154 <lb/>Yu F, Wang Q, Zhang Z, Peng Y, Qiu Y, Shi Y, Zheng Y, Xiao S, <lb/>Wang H, Huang X, Zhu L, Chen K, Zhao C, Zhang C, Yu M, Sun <lb/>D, Zhang L, Zhou D (2013) Development of oleanane-type tri-<lb/>terpenes as a new class of HCV entry inhibitors. J Med Chem <lb/>56:4300-4319 <lb/></listBibl>

			<note place="headnote">Medicinal Chemistry Research (2018) 27:2051-2061 <lb/></note>

			<page>2061 </page>


	</text>
</tei>